-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor-

- Phase 3 ADMIRAL trial showed patients treated with XOSPATA demonstrated longer Overall Survival than those who received salvage chemotherapy[1] -

-Total Funds To Be Awarded Increased to $200,000; All Encouraged to Apply -

- Data Presented at the American Urological Association 2019 Annual Meeting -

- Study results will be presented at American Association for Cancer Research Annual Meeting 2019 -

- Companies Plan to Submit Biologics License Application Later This Year -

- Investigational compound fezolinetant reduced frequency and severity of vasomotor symptoms in postmenopausal women -

Joint Project Will Explore Enhancements to Patient Communication and Shared Decision-Making

Data to be presented at the 2019 Genitourinary Cancers Symposium

Acquisition adds clinical stage novel immuno-oncology programs to Astellas' oncology pipeline

- FLT3 mutation-positive AML is a life-threatening disease[1] with significant unmet medical needs -

Navigation Acuity Tool to be Developed by Astellas US LLC and AONN+

- Abstracts include updated results from Phase 1 study of gilteritinib in patients with newly diagnosed AML -

Three innovators working to change cancer care awarded a combined $100,000 in grants following live pitch to a panel of judges that included celebrity entrepreneur Bill Rancic

Astellas ranked in recognition of its commitment and support for working mothers

Astellas recognized by Great Place to Work® Institute

Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs 14.7 months for men who received placebo plus ADT(1)

Bill and Giuliana Rancic to Lend Expertise, Passion and Personal Cancer Experience to Inspire Fellow Entrepreneurs

--Additional marketing award received for Best Video/TV Campaign--

Winner Will Attend Live Taping of ABC's "Dancing with the Stars"

Amendments accelerate anticipated primary completion dates for both ARCHES and EMBARK trials

Acquisition furthers Astellas' commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma

Dr. Halit Bander named VP, Oncology, Medical Affairs; Moyra Knight named VP, Corporate Communications; Maribeth Landwehr named Executive Director, Corporate Communications

First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC

-Enrollment of EV-201 Pivotal Trial Cohort Designed to Support Potential Expedited Registration Pathway in the U.S. Completed-

Employees Also Raised More Than $55,000 at Third Annual "One Astellas Spirit Run" for Seven Charitable Organizations

-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study-

2018 Challenge Will Award a Total of $100,000 in New Grants to Help Reduce the Unequal Burden of Cancer